Skip to content
Comparison

Zepbound (Tirzepatide) vs Ozempic (Semaglutide)

Zepbound (tirzepatide 2.5–15 mg) and Ozempic (semaglutide 0.5–2.0 mg) are both weekly GLP-1-based injections by Eli Lilly and Novo Nordisk respectively, but they are FDA-approved for different primary indications — Zepbound for chronic weight management and obstructive sleep apnea, Ozempic for type 2 diabetes. Comparing them is popular because many patients use both medications off-label for weight loss, and because Ozempic is often the first GLP-1 people encounter. Zepbound's active ingredient (tirzepatide) produces substantially more weight loss than Ozempic's active ingredient (semaglutide 2 mg used in T2D), but Ozempic has 7+ years of real-world safety data and a proven cardiovascular benefit from the SUSTAIN-6 trial.

4.3(112 ratings)

Quick Answer

Zepbound and Ozempic are different drugs: Zepbound (tirzepatide) is FDA-approved for obesity; Ozempic (semaglutide) is approved for type 2 diabetes. Both can aid weight loss, but Zepbound produces far more — about 20–22.5% body weight loss vs Ozempic's 6–9% at T2D doses. For weight loss, Wegovy (semaglutide 2.4 mg) is the proper comparison to Zepbound, not Ozempic. Ozempic has proven cardiovascular benefit (SUSTAIN-6 and SELECT-derived data). Consult your provider about which fits your primary diagnosis and coverage.

Head-to-Head Comparison

CriteriaZepbound (Tirzepatide)Ozempic (Semaglutide)
Active ingredientTirzepatide — dual GIP + GLP-1 receptor agonistSemaglutide 0.5–2.0 mg — GLP-1 receptor agonist only
Primary FDA indicationChronic weight management + obstructive sleep apneaType 2 diabetes mellitus (Ozempic); weight management uses Wegovy brand
Dosing scheduleOnce weekly subcutaneous injection (2.5 → 15 mg over ~20 weeks)Once weekly subcutaneous injection (0.25 → max 2.0 mg over ~8 weeks)
Average weight loss~20–22.5% body weight (SURMOUNT-1 at 15 mg, 88 weeks)~6–9% body weight at Ozempic doses (T2D trials); 14.9% at Wegovy 2.4 mg (obesity trial)
A1C reduction (T2D)~2.0–2.3% (SURPASS program, Mounjaro doses)~1.5–1.8% (SUSTAIN program, Ozempic doses)
Cardiovascular outcomes evidenceSURMOUNT-CVOT ongoing; select secondary endpoints show benefit26% MACE reduction vs placebo in SUSTAIN-6 (T2D with CVD); SELECT trial proven CV benefit at Wegovy dose
Half-life~5 days~7 days
US list price (2026)~$1,060–$1,200/month (Zepbound)~$935–$1,000/month (Ozempic)
Insurance coverageCovered under obesity/weight management benefits; not labeled for T2DWidely covered for T2D; not labeled for obesity (Wegovy is the obesity brand)
Oral formulationNo approved oral form (Phase 3 oral tirzepatide trials ongoing)Rybelsus (oral semaglutide) available for T2D; not for weight loss
Years on market~2 years (Zepbound, Nov 2023)~7 years (Ozempic, Dec 2017)

When to Choose Each

Choose Zepbound (Tirzepatide)

Adults with obesity seeking maximum weight reduction, patients with both obesity and T2D who want stronger efficacy on both weight and glucose endpoints, those with obstructive sleep apnea and obesity, or patients who have plateaued on semaglutide.

Choose Ozempic (Semaglutide)

Adults with type 2 diabetes as the primary diagnosis (especially with established cardiovascular disease given SUSTAIN-6 and SELECT cardiovascular benefit), patients who prefer the longer safety track record, or those whose insurance covers Ozempic for T2D but not Zepbound.

Verdict

Zepbound and Ozempic serve overlapping but distinct roles — comparing them directly is somewhat misleading because they are approved for different primary indications. For weight loss specifically, Zepbound (tirzepatide) produces substantially more weight loss than Ozempic at its T2D doses; the proper obesity comparison is Zepbound vs Wegovy. For patients primarily managing type 2 diabetes, Ozempic has a deeper clinical evidence base, 7+ years of real-world safety data, and proven cardiovascular event reduction. For patients whose primary goal is weight loss (regardless of T2D status), Zepbound is generally the superior evidence-based choice. Discuss your primary diagnosis, cardiovascular history, and insurance coverage with your provider to determine the appropriate prescription.

References

  1. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
  2. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed
  3. Semaglutide 2.0 mg versus 1.0 mg for type 2 diabetes (SUSTAIN-11) (2021) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) (2016) — PubMed
  5. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed
  6. Tirzepatide for moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA) (2024) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

From $199/moLearn More →
Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →
Ro BodyBest Value

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

From $149/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

What is the difference between Zepbound and Ozempic?
Zepbound (tirzepatide) and Ozempic (semaglutide) differ in active ingredient, mechanism, and FDA indication. Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a GLP-1 receptor agonist only. Ozempic is approved for type 2 diabetes; Zepbound is approved for obesity and obstructive sleep apnea. For obesity, the proper semaglutide comparison is Wegovy (2.4 mg), not Ozempic (max 2 mg). Zepbound produces considerably more weight loss than Ozempic at its T2D doses.
Can I use Ozempic for weight loss if I don't have diabetes?
Ozempic is FDA-approved only for type 2 diabetes. A physician can prescribe it off-label for weight loss, and it does produce weight loss — but at Ozempic doses (up to 2 mg), average weight loss is about 6–9%. For weight management in patients without T2D, Wegovy (semaglutide 2.4 mg) is the FDA-approved obesity drug. Most insurers will only cover obesity medications under obesity benefit riders, not T2D diabetes benefits. If weight loss is your primary goal, ask your provider about Wegovy or Zepbound.
Is tirzepatide (Zepbound) stronger than semaglutide (Ozempic)?
When comparing tirzepatide at obesity doses vs semaglutide at T2D doses, tirzepatide produces substantially more weight loss — approximately 20–22.5% vs 6–9%. Even comparing tirzepatide to semaglutide at the higher obesity dose (Wegovy 2.4 mg), tirzepatide still produces roughly 7–8 percentage points more weight loss (22.5% vs 14.9%). For A1C reduction in T2D, SURPASS-2 found tirzepatide superior at all doses vs semaglutide.
Which has better cardiovascular evidence — Zepbound or Ozempic?
Ozempic (semaglutide) currently has stronger and more established cardiovascular evidence. The SUSTAIN-6 trial demonstrated a 26% reduction in MACE in T2D patients with high CV risk. The SELECT trial (using Wegovy-dose semaglutide) showed 20% MACE reduction in patients with obesity and established CVD. Zepbound's cardiovascular outcomes trial (SURMOUNT-CVOT) is ongoing. For patients with T2D and established cardiovascular disease, Ozempic's proven CV benefit is clinically meaningful.
How do insurance companies treat Zepbound vs Ozempic?
Most commercial insurers treat Zepbound and Ozempic as completely separate products under separate benefit categories. Ozempic is typically covered under diabetes drug benefits for patients with T2D. Zepbound is covered under obesity/weight management benefits, which fewer plans include. Some plans cover both, some neither. Medicare Part D does not cover Wegovy or Zepbound for obesity (as of 2026, pending legislative changes), but does cover Ozempic for T2D. Prior authorization rules typically require using the drug approved for your specific diagnosis.
Which drug causes more nausea — Zepbound or Ozempic?
Direct comparison data comes from trials comparing tirzepatide vs semaglutide at respective labeled doses. At T2D doses, tirzepatide in SURPASS-2 showed 31% nausea vs 44% for semaglutide. At obesity doses, Zepbound in SURMOUNT-1 showed approximately 31% nausea; Wegovy (2.4 mg semaglutide) in STEP-1 showed approximately 44%. Both drugs cause GI side effects that typically peak during dose escalation and improve after 4–8 weeks. Slower titration helps reduce both.

Explore next